DJIA 16,380.41 0.00 0.00%
NASDAQ 4,258.44 0.00 0.00%
S&P 500 1,886.76 0.00 0.00%
market minute promo

Gilead Sciences (NASDAQ: GILD)

100.75 0.00 (0.00%)

REAL-TIME: Last trade at

Extended Hours: $101.59 $0.84 (0.83%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

GILD $100.75 0.00%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.00
Previous Close $100.75
Daily Range $0.00 - $0.00
52-Week Range $63.50 - $110.64
Market Cap $152.3B
P/E Ratio 22.69
Dividend (Yield) $0.00 (0.0%)
Volume 14,690
Average Daily Volume 14,818,205
Current FY EPS $7.26

Sector

Healthcare

Industry

Drugs

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

News & Commentary Rss Feed

What Johnson & Johnson Can Tell Us about Gilead Sciences, inc. Stock

Slipping sales for Johnson & Johnson's hepatitis C drug Olysio may give Gilead investors reason for pause.

Gilead: Stage Set For Rally

#PreMarket Primer: Monday, October 20: Fed To Tread Softly At October Meeting

End Of The Year Events To Drive Some Of October's Beaten Up Biotech Companies

This Drug Could Outsell Medical Marijuana

Three top motley fool analysts weigh in on drugs from Gilead Sciences, Biogen, Bristol-Myers, and Merck that could be bigger sellers than medical marijuana.

180 Million People Have This Disease, Yet Few Are Aware of It

75% of people with this potentially deadly disease are clueless they have it. Yet the interesting thing is we have the tools needed to practically eradicate it.

Cramer's Lightning Round - Ensco Is One Of The Worst Stocks I've Owned In My Life (10/17/14)

Could This Game-Changing Drug Deliver $10 Billion in Sales Within Its First Year?

This recently approved drug has record-breaking potential and could top $10 billion in sales within its first year. Find out the name of this drug and the company behind it.

'Mad Money' Lightning Round: Lots of Ways to Win With Molson Coors

Gilead's Harvoni Receives Notice of Compliance from Canada - Analyst Blog

See More GILD News...

GILD's Top Competitors

GILD $100.75 (0.00%)
Current stock: GILD
AMGN $133.69 (0.00%)
Current stock: AMGN
CELG $88.12 (0.00%)
Current stock: CELG
$0.00 (0.00%)
Current stock: